Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Methylprednisolone Aceponate→

Methylprednisolone Aceponate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
86401-95-8
Molecular formula
C27H36O7
Molecular weight
472.6 g/mol
Drug class
Topical glucocorticoidcorticosteroid receptor agonist
Mechanism of action
Activates intracellular glucocorticoid receptors in skin, suppressing inflammatory cytokines, leukocyte migration and other immune responses, thereby reducing erythema, oedema and pruritus.
Indications / reported uses
  • Short-term topical treatment of corticosteroid-responsive inflammatory skin conditions, including eczema and dermatitis, using the appropriate potency and formulation; do not assign systemic glucocorticoid indications to the topical aceponate preparation

Sources: UK product information — Advantan (methylprednisolone aceponate) · EMA — Methylprednisolone aceponate product information · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Topical glucocorticoid; corticosteroid receptor agonist

Mechanism of action

Activates intracellular glucocorticoid receptors in skin, suppressing inflammatory cytokines, leukocyte migration and other immune responses, thereby reducing erythema, oedema and pruritus.

General use cases

  • Short-term topical treatment of corticosteroid-responsive inflammatory skin conditions, including eczema and dermatitis, using the appropriate potency and formulation; do not assign systemic glucocorticoid indications to the topical aceponate preparation

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Methylprednisolone Aceponate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Methylprednisolone Aceponate Permitted Daily Exposure (PDE) report (the Methylprednisolone Aceponate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Methylprednisolone Aceponate Occupational Exposure Limit (OEL) report (the Methylprednisolone Aceponate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.